Osteonecrosis of the Jaw in Patients with Multiple Myeloma Treated with Bisphosphonates: Definition and Management of the Risk Related to Zoledronic Acid

Autor: Cafro, Anna Maria, Barbarano, Luciana, Nosari, Anna Maria, D'Avanzo, Giovanna, Nichelatti, Michele, Bibas, Michele, Gaglioti, Domenico, Taroni, Alberto, Riva, Francesco, D'Avanzo, Giovanna, Andriani, Alessandro
Zdroj: Clinical Lymphoma and Myeloma; April 2008, Vol. 8 Issue: 2 p111-116, 6p
Abstrakt: Bisphosphonates (BPs) are currently used to treat bone lesions in patients with multiple myeloma (MM). Osteonecrosis of the jaw (ONJ) has been reported as an adverse event of such treatment, especially after treatment with zoledronic acid (ZA). The aim of this study was to evaluate incidence, risk factors, management, and prevention strategies of ONJ in order to optimize the current standard use of BPs in MM.
Databáze: Supplemental Index
Externí odkaz: